мавенклад 10 мг 1

Mavenclad® 10mg

cladribine

MAVENCLAD (cladribine tablets) is indicated in patients* with highly active relapsing MS and is the only** DMD that can deliver and sustain 4 years of disease control† with a maximum of 20 days of oral treatment in the first 2 years.
Summary report on drug properties
discover MAVENCLAD®

INDICATIONS

MAVENCLAD is indicated for the treatment of adult patients with highly active relapsing multiple
sclerosis (MS) as defined by clinical or imaging features (MRI).

FOOTnotes AND REFERENCES

*MAVENCLAD‭‭ is indicated for the treatment of adult patients with highly active RMS as defined by clinical or imaging feature‭s‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬

**There are currently no head-to-head trials. From publicly available information, accurate at date of creation – September 2018

†Disease control refers to 75.6% of patients who remained relapse-free without further treatment in Years 3 and 43

††See Rebif prescribing information for more details.

  1. MAVENCLAD® SmPC, 2017.
  2. Giovannoni G et al. N Engl J Med 2010; 362:416–426.
  3. Giovannoni G et al. EAN 2017; [P0542].
  4. Giovannoni G et al. Mult Scler 2017; doi: 10.1177/1352458517727603.
  5. Rebif® EU Summary of Product Characteristics, December 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf [Accessed 25 April 2018].
  6. De Stefano N et al. J Neurol Sci 2012; 312:97–101.
  7. Kappos L et al. J Neurol Neurosurg Psychiatry 2015; 86:1202–1207

DMD – disease modifying drug

MRI – magnetic resonance imaging

MS – multiple sclerosis

RMS – relapsing multiple sclerosis